Armata Pharmaceuticals Inc
For the period ended Mar 31, 2024. Filed May 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 7, 2024
ARMP$3.80+8.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
| | | | | | | |
|---|---|---|---|---|---|---|
| | March 31, 2024 | December 31, 2023 | ||||
| Assets | | | | | | |
| Current assets | | | | | | |
| Cash | | $37,860 | | $13,523 | ||
| Prepaid expenses and other current assets | | 2,143 | | 2,265 | ||
| Other receivables | | | 1,714 | | | 3,363 |
| Total current assets | | 41,717 | | 19,151 | ||
| Restricted cash | | | 5,480 | | | 5,720 |
| Property and equipment, net | | 12,700 | | 12,559 | ||
| Operating lease right-of-use asset | | 44,243 | | 44,717 | ||
| In-process research and development | | | 10,256 | | | 10,256 |
| Goodwill | | | 3,490 | | | 3,490 |
| Other assets | | 2,470 | | 2,470 | ||
| Total assets | | $120,356 | | $98,363 | ||
| | | | | | | |
| Liabilities and stockholders’ deficit | | | ||||
| Current liabilities | | | ||||
| Accounts payable and accrued liabilities | | $4,610 | | $5,689 | ||
| Accrued compensation | | | 948 | | | 768 |
| Convertible debt | | | 71,658 | | | — |
| Term debt, current | | | 25,010 | | | — |
| Current portion of operating lease liabilities | | | 7,497 | | | 9,481 |
| Other current liabilities | | | 322 | | | 523 |
| Total current liabilities | | 110,045 | | 16,461 | ||
| Operating lease liabilities, net of current portion | | | 28,376 | | | 28,583 |
| Convertible debt | | | — | | | 58,633 |
| Term debt, non-current | | | 35,368 | | | 23,674 |
| Deferred tax liability | | | 3,077 | | | 3,077 |
| Total liabilities | | 176,866 | | 130,428 | ||
| | | | | | | |
| Commitments and contingencies (Note 12) | | | ||||
| Stockholders’ deficit | | | ||||
| Common stock, $0.01 par value; 217,000,000 shares authorized; 36,132,117 and 36,122,932 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | | 361 | | 361 | ||
| Additional paid-in capital | | 276,969 | | 276,393 | ||
| Accumulated deficit | | (333,840) | | (308,819) | ||
| Total stockholders’ deficit | | (56,510) | | (32,065) | ||
| Total liabilities and stockholders’ deficit | | $120,356 | | $98,363 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.